Top

Pediatric Drugs

Published in:

01-02-2012 | Review Article

Management of Pediatric Eosinophilic Esophagitis

An Update

Author: Dr Seema Khan

Published in: Pediatric Drugs | Issue 1/2012

Abstract

Eosinophilic esophagitis is an important chronic esophageal disorder with gastroesophageal reflux disease (GERD)-like symptoms, prominent esophageal mucosal eosinophilia, strongly associated with allergic disorders and unresponsive to anti-GERD therapy. Treatment of eosinophilic esophagitis has been successful with the use of dietary restrictions and topical corticosteroids. A subset of patients benefits from concurrent anti-GERD therapy; those with demonstrable esophageal strictures report variable duration symptom relief after esophageal dilation. At the current time, anti-interleukin-5 monoclonal antibody agents are being investigated in multicenter trials, and it is hoped that future therapy may be targeted against mediators of esophageal remodeling and fibrosis in eosinophilic esophagitis.

Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128(1): 3–20.e6PubMedCrossRef

Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133(4): 1342–63PubMedCrossRef

Furuta GT, Forbes D, Boey C, et al. Eosinophilic gastrointestinal diseases (EGIDs). J Pediatr Gastroenterol Nutr 2008; 47(2): 234–8PubMedCrossRef

Rothenberg ME, Spergel JM, Sherrill JD, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet 2010; 42(4): 289–91PubMedCrossRef

Khan S, Orenstein SR. Eosinophilic gastroenteritis: epidemiology, diagnosis and management. Paediatr Drugs 2002; 4: 563–70PubMed

Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006; 131(5): 1381–91PubMedCrossRef

Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010; 59(1): 21–30PubMedCrossRef

Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010; 139(2): 418–29PubMedCrossRef

Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010; 139(5): 1526–37, 1537.e1PubMedCrossRef

10.

Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009; 137(4): 1238–49PubMedCrossRef

11.

Lucendo AJ, Lucendo B. An update on the immunopathogenesis of eosinophilic esophagitis. Expert Rev Gastroenterol Hepatol 2010; 4(2): 141–8PubMedCrossRef

12.

Putnam PE, Rothenberg ME. Eosinophilic esophagitis: concepts, controversies, and evidence. Curr Gastroenterol Rep 2009; 11(3): 220–5PubMedCrossRef

13.

Whitney-Miller CL, Katzka D, Furth EE. Eosinophilic esophagitis: a retrospective review of esophageal biopsy specimens from 1992 to 2004 at an adult academic medical center. Am J Clin Pathol 2009; 131(6): 788–92PubMedCrossRef

14.

Mishra A. Mechanism of eosinophilic esophagitis. Immunol Allergy Clin North Am 2009; 29(1): 29–40, viiiPubMedCrossRef

15.

Kapel RC, Miller JK, Torres C, et al. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008; 134(5): 1316–21PubMedCrossRef

16.

Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009; 48(1): 30–6PubMedCrossRef

17.

Cherian S, Smith NM, Forbes DA. Rapidly increasing prevalence of eosinophilic oesophagitis in Western Australia. Arch Dis Child 2006; 91(12): 1000–4PubMedCrossRef

18.

Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol 2005; 115(2): 418–9PubMedCrossRef

19.

Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3(12): 1198–206PubMedCrossRef

20.

Orenstein SR, Shalaby TM, Di Lorenzo C, et al. The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children. Am J Gastroenterol 2000; 95(6): 1422–30PubMedCrossRef

21.

Ronkainen J, Talley NJ, Aro P, et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut 2007; 56(5): 615–20PubMedCrossRef

22.

Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004; 351(9): 940–1PubMedCrossRef

23.

Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2009; 7(10): 1055–61PubMedCrossRef

24.

Spergel JM, Book WM, Mays E, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr 2011; 52(3): 300–6PubMedCrossRef

25.

Mishra A, Hogan SP, Brandt EB, et al. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 2001; 107(1): 83–90PubMedCrossRef

26.

Mishra A, Hogan SP, Brandt EB, et al. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 2002; 168(5): 2464–9PubMed

27.

Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003; 125(5): 1419–27PubMedCrossRef

28.

Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006; 116(2): 536–47PubMedCrossRef

29.

Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995; 109(5): 1503–12PubMedCrossRef

30.

Markowitz JE, Spergel JM, Ruchelli E, et al. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003; 98(4): 777–82PubMedCrossRef

31.

Blanchard C, Wang N, Rothenberg ME. Eosinophilic esophagitis: patho-genesis, genetics, and therapy. J Allergy Clin Immunol 2006; 118(5): 1054–9PubMedCrossRef

32.

Spergel JM, Andrews T, Brown-Whitehorn TF, et al. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005; 95(4): 336–43PubMedCrossRef

33.

Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006; 4(9): 1097–102PubMedCrossRef

34.

Teitelbaum JE, Fox VL, Twarog FJ, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002; 122(5): 1216–25PubMedCrossRef

35.

Liacouras CA, Wenner WJ, Brown K, et al. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998; 26(4): 380–5PubMedCrossRef

36.

Faubion Jr WA, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 1998; 27(1): 90–3PubMedCrossRef

37.

Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2004; 2(7): 568–75PubMedCrossRef

38.

Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006; 63(1): 3–12PubMedCrossRef

39.

Katz PO. Eosinophilic esophagitis in adults: clinical, endoscopic, and histologic findings, and response to treatment with fluticasone propionate. Rev Gastroenterol Disord 2006; 6(4): 245–7PubMed

40.

Lucendo AJ, Pascual-Turrion JM, Navarro M, et al. Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. Endoscopy 2007; 39(9): 765–71PubMedCrossRef

41.

Caldwell JM, Blanchard C, Collins MH, et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. J Allergy Clin Immunol 2010; 125(4): 879–88.e8PubMedCrossRef

42.

Lucendo AJ, De Rezende L, Comas C, et al. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL1 1, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. Am J Gastroenterol 2008; 103(9): 2184–93PubMedCrossRef

43.

Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008; 6(2): 165–73PubMedCrossRef

44.

Helou EF, Simonson J, Arora AS. 3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults. Am J Gastroenterol 2008; 103(9): 2194–9PubMedCrossRef

45.

Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010; 55(5): 1313–9PubMedCrossRef

46.

Abu-Sultaneh SM, Durst P, Maynard V, et al. Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Dig Dis Sci 2011; 56(1): 97–102PubMedCrossRef

47.

Aceves SS, Dohil R, Newbury RO, et al. Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2005; 116(3): 705–6PubMedCrossRef

48.

Aceves SS, Bastian JF, Newbury RO, et al. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol 2007; 102(10): 2271–9; quiz 2280PubMedCrossRef

49.

Krishna SG, Kakati BR, Olden KW, et al. Treatment of eosinophilic esophagitis: is oral viscous budesonide superior to swallowed fluticasone spray? Gastroenterol Hepatol (N Y) 2011; 7(1): 55–9

50.

Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003; 52(2): 181–5PubMedCrossRef

51.

Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus 2011; 24(4): 229–34PubMedCrossRef

52.

Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009; 49(4): 393–9PubMedCrossRef

53.

Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011; 9(2): 110–7PubMedCrossRef

54.

Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus: peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol, 2006; 101(7): 1666–70PubMedCrossRef

55.

Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009; 104(3): 716–21PubMedCrossRef

56.

Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007; 102(6): 1301–6PubMedCrossRef

57.

Merwat SN, Spechler SJ. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol 2009; 104(8): 1897–902PubMedCrossRef

58.

Egan RW, Athwahl D, Chou CC, et al. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Immunol 1995; 107(1–3): 321–2PubMedCrossRef

59.

Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009; 11(3): 329–36PubMed

60.

Walsh GM. Reslizumab for pediatric eosinophilic esophagitis. Immunotherapy 2010; 2(4): 461–5PubMedCrossRef

61.

Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004; 114(6): 1449–55PubMedCrossRef

62.

Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113(1): 115–9PubMedCrossRef

63.

Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006; 118(6): 1312–9PubMedCrossRef

64.

Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008; 122(2): 425–7PubMedCrossRef

65.

Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosi-nophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010; 105(5): 1062–70PubMedCrossRef

66.

Lee GS, Craig PI, Freiman JS, et al. Intermittent dysphagia for solids associated with a multiringed esophagus: clinical features and response to dilatation. Dysphagia 2007; 22(1): 55–62PubMedCrossRef

67.

Jacobs Jr JW, Spechler SJ. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci 2010; 55(6): 1512–5PubMedCrossRef

68.

Jung KW, Gundersen N, Kopacova J, et al. Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis. Gastrointest Endosc 2011; 73(1): 15–21PubMedCrossRef

69.

Schoepfer AM, Gschossman J, Scheurer U, et al. Esophageal strictures in adult eosinophilic esophagitis: dilation is an effective and safe alternative after failure of topical corticosteroids. Endoscopy 2008; 40(2): 161–4PubMedCrossRef

70.

Bohm M, Richter JE, Kelsen S, et al. Esophageal dilation: simple and effective treatment for adults with eosinophilic esophagitis and esophageal rings and narrowing. Dis Esophagus 2010; 23(5): 377–85PubMed

Title: Management of Pediatric Eosinophilic Esophagitis
An Update
Author: Dr Seema Khan
Publication date: 01-02-2012
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 1/2012
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.2165/11595210-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Management of Pediatric Eosinophilic Esophagitis

An Update

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Everolimus

Pharmacovigilance in Pediatrics

Candesartan Cilexetil in Children and Adolescents Aged 1 to <17 Years with Hypertension

Anesthetic-Related Neurotoxicity and the Developing Brain

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]

Defining Juvenile Idiopathic Arthritis Remission and Optimum Time for Disease-Modifying Anti-Rheumatic Drug Withdrawal